Latest Tech News

Stay updated with the latest in technology, AI, cybersecurity, and more

Filtered by: medications Clear Filter

Ozempic Users Can Now Workout With Apple Fitness Plus Through New Weight-Loss Partnership

If you're a FuturHealth member, you'll now have a free membership to Apple Fitness Plus as part of your program. It's Apple Fitness Plus’s first direct integration with a personalized GLP-1 weight-loss program. FuturHealth offers personalized weight-loss guidance and medications with the help of licensed dietitians and doctors. These include GLP-1 agonists such as semaglutide -- better known as Ozempic. It's partnered with Valisure, a tech company that provides independent quality assurance, to

Apple Fitness Plus Targets Ozempic Users With New Weight-Loss Partnership

If you're a FuturHealth member, you'll now have a free membership to Apple Fitness Plus as part of your program. It's Apple Fitness Plus’s first direct integration with a personalized GLP-1 weight loss program. FuturHealth offers personalized weight loss guidance and medications with the help of licensed dietitians and doctors. These include GLP-1 agonists such as semaglutide -- better known as Ozempic. It's partnered with Valisure, a tech company that provides independent quality assurance, to

Apple Fitness Plus Targets GLP-1 Users With New Weight-Loss Partnership

If you're a FuturHealth member, you'll now have a free membership to Apple Fitness Plus as part of your program. It's Apple Fitness Plus’s first direct integration with a personalized GLP-1 weight loss program. FuturHealth offers personalized weight loss guidance and medications with the help of licensed dietitians and doctors. These include GLP-1 agonists such as semaglutide -- better known as Ozempic. It's partnered with Valisure, a tech company that provides independent quality assurance, to

Shares of Hims & Hers tumble 26% after FDA says semaglutide is no longer in shortage

Shares of Hims & Hers Health closed down around 26% on Friday after the U.S. Food and Drug Administration announced that the shortage of semaglutide injection products has been resolved. Semaglutide is the active ingredient in Novo Nordisk's blockbuster weight loss drug Wegovy and diabetes treatment Ozempic. Those medications are part of a class of drugs called GLP-1s, and demand for the treatments has exploded in recent years. As a result, digital health companies such as Hims & Hers have been